Cellectis ADR

CLLSNASDAQ · USD
1.07USD+0.01 (+0.48%)
622

Cellectis ADR (CLLS) Covered Calls

Cellectis ADR trades in the Biotechnology industry with an IV Rank of 8.33%, low versus the past year. CLLS's highest covered call setup is the $2.50 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 140.38% out of the money with 186 days to expiration, a 145.19% return until expiration, and a 284.92% theoretical annualized return. Across the setups shown, annualized returns run from 284.92% to 284.92% at strikes between $2.50 and $2.50, with 186 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running CLLS covered calls helps you generate income from Cellectis ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CLLS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CLLS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CLLS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CLLS covered call is worth writing.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

2027-05-211862.50140.380.054.80151.00145.19284.92-4.81+1.00744.75

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank8.33% Low
  • Market cap (M$)77
  • 52 weeks high-80.55%
  • 52 weeks low20.45%
  • Analyst recommendationHold
    2.57
  • Target price$4.75
    369.48% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-13
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.65
  • EPS growth next 5 years-28.02%

As of Nov 17, 2026